Cryo-Cell International (Cryo-Cell International) Total Liabilities

: $72.05 Mil (As of Feb. 2024)

View and export this data going back to . Start your Free Trial

Cryo-Cell International's Total Liabilities for the quarter that ended in Feb. 2024 was $72.05 Mil.

Cryo-Cell International's quarterly Total Liabilities increased from Aug. 2023 ($69.81 Mil) to Nov. 2023 ($72.25 Mil) but then declined from Nov. 2023 ($72.25 Mil) to Feb. 2024 ($72.05 Mil).

Cryo-Cell International's annual Total Liabilities increased from Nov. 2021 ($56.48 Mil) to Nov. 2022 ($66.41 Mil) and increased from Nov. 2022 ($66.41 Mil) to Nov. 2023 ($72.25 Mil).

Cryo-Cell International Total Liabilities Historical Data

The historical data trend for Cryo-Cell International's Total Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Cryo-Cell International Annual Data

Trend

Nov14

Nov15

Nov16

Nov17

Nov18

Nov19

Nov20

Nov21

Nov22

Nov23

Total Liabilities

49.84

48.87

56.48

66.41

72.25

Cryo-Cell International Quarterly Data
	May19	Aug19	Nov19	Feb20	May20	Aug20	Nov20	Feb21	May21	Aug21	Nov21	Feb22	May22	Aug22	Nov22	Feb23	May23	Aug23	Nov23	Feb24
Total Liabilities																66.82	69.62	69.81	72.25	72.05

Cryo-Cell International Total Liabilities Calculation

Total Liabilities are the liabilities that the company has to pay others. It is a part of the balance sheet of a company that shareholders do not own, and would be obligated to pay back if the company liquidated.

Cryo-Cell International's Total Liabilities for the fiscal year that ended in Nov. 2023 is calculated as

Total Liabilities	=	Total Current Liabilities	+	Total Noncurrent Liabilities
	=	Total Current Liabilities	+	(Long-Term Debt & Capital Lease Obligation	+	Other Long-Term Liabilities
	=	20.864	+	(9.282	+	0.919
	+	NonCurrent Deferred Liabilities	+	PensionAndRetirementBenefit)
	+	41.187	+	0)
	=	72.25

Total Liabilities	=	Total Assets (A: Nov. 2023 )	-	Total Equity (A: Nov. 2023 )
	=	61.221	-	-11.031
	=	72.25

Cryo-Cell International's Total Liabilities for the quarter that ended in Feb. 2024 is calculated as

Total Liabilities	=	Total Current Liabilities	+	Total Noncurrent Liabilities
	=	Total Current Liabilities	+	(Long-Term Debt & Capital Lease Obligation	+	Other Long-Term Liabilities
	=	19.37	+	(9.161	+	0.914
	+	NonCurrent Deferred Liabilities	+	PensionAndRetirementBenefit)
	+	42.604	+	0)
	=	72.05

Total Liabilities	=	Total Assets (Q: Feb. 2024 )	-	Total Equity (Q: Feb. 2024 )
	=	61.711	-	-10.338
	=	72.05

Cryo-Cell International Total Liabilities Related Terms

Thank you for viewing the detailed overview of Cryo-Cell International's Total Liabilities provided by GuruFocus.com. Please click on the following links to see related term pages.

Cryo-Cell International (Cryo-Cell International) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Healthcare Providers & Services » Cryo-Cell International Inc (AMEX:CCEL) » Definitions » Total Liabilities

Comparable Companies

Traded in Other Exchanges

ZCY:Germany

Address

700 Brooker Creek Boulevard, Suite 1800, Oldsmar, FL, USA, 34677

Website

https://www.cryo-cell.com

Cryo-Cell International Inc is engaged in cellular processing and cryogenic storage. The company is organized into three reportable segments namely cellular processing and cryogenic storage, with a focus on the collection and preservation of umbilical cord blood and tissue stem cells for family use and the manufacturing of Prepacyte CB units segment, which is a processing technology used to process umbilical cord blood stem cells. The Public cord blood banking segment consists of cellular processing and cryogenic storage of umbilical cord blood stem cells for public use. All the business activity of the group functions through the United States and it derives revenue from processing and testing fees and storage fees charged each year for storage and through sales of the Prepacyte CB units.

Executives

David Portnoy	director, officer: Co-Chief Executive Officer	C/O FOCUS FINANCIAL GROUP, 61 HARBOUR WAY, BAL HARBOUR FL 33154
George Gaines	director	700 BROOKER CREEK BLVD, SUITE 1800, OLDSMAR FL 34677
Jonathan H. Wheeler	director	700 BROOKER CREEK BLVD, SUITE 1800, OLDSMAR FL 34677
Brian L. Sheehy	director	415 MADISON AVENUE, 14TH FLOOR, NEW YORK NY 10017
Mark L. Portnoy	director, officer: Co-Chief Executive Officer	700 BROOKER CREEK BLVD, SUITE 1800, OLDSMAR FL 34677
Harold D. Berger	director	700 BROOKER CREEK BLVD, SUITE 1800, OLDSMAR FL 34677
Arthur Ellis	director	700 BROOKER CREEK BLVD, SUITE 1800, OLDSMAR FL 34677
Mary J Nyberg	10 percent owner	455 E MAYO BLVD, UNIT 5202, PHOENIX AZ 85050
Cdmj Nyberg Family Trust	10 percent owner	455 E MAYO BLVD, UNIT 5202, PHOENIX AZ 85050
Jill M Taymans	officer: VP, Finance, CFO
Oleg Mikulinsky	officer: Chief Information Officer	700 BROOKER CREEK BLVD., SUITE 1800, OLDSMAR FL 34677
Anthony Atala	director	700 BROOKER CREEK BOULEVARD, OLDSMAR FL 34677
Scott G Christian	director
Sung Won Sohn	director	700 BROOKER CREEK BLVD., SUITE 1800, OLDSMAR FL 34677
Michael W. Cho	director	C/O IOWA STATE UNIVERSITY, 1600 S. 16TH STREET, AMES IA 50011-1250